Sumitomo Life Insurance Co. Acquires 3,954 Shares of AbbVie Inc. $ABBV

Sumitomo Life Insurance Co. increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 25.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,314 shares of the company’s stock after acquiring an additional 3,954 shares during the period. Sumitomo Life Insurance Co.’s holdings in AbbVie were worth $4,413,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of ABBV. Norges Bank bought a new stake in AbbVie during the fourth quarter worth about $5,865,055,000. Wellington Management Group LLP boosted its stake in AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares in the last quarter. Capital World Investors boosted its stake in AbbVie by 106.3% during the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after acquiring an additional 6,736,161 shares in the last quarter. Geode Capital Management LLC boosted its stake in AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after acquiring an additional 4,190,487 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in AbbVie by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after acquiring an additional 3,032,438 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 1.2%

ABBV opened at $227.54 on Friday. The firm has a 50 day moving average price of $211.05 and a 200-day moving average price of $219.07. AbbVie Inc. has a twelve month low of $181.73 and a twelve month high of $244.81. The stock has a market capitalization of $402.02 billion, a price-to-earnings ratio of 112.09, a PEG ratio of 0.69 and a beta of 0.32.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the previous year, the company earned $2.46 earnings per share. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. As a group, analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current year.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Analyst Ratings Changes

Several equities research analysts recently commented on ABBV shares. Guggenheim reissued a “buy” rating and set a $249.00 price objective on shares of AbbVie in a research note on Friday, May 1st. William Blair reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Barclays initiated coverage on shares of AbbVie in a research note on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective on the stock. Royal Bank Of Canada initiated coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price on the stock. Finally, Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, June 7th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.